News Sentiment

ABBV sentiment intelligence

AbbVie Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors Options RSS feed
Weighted score 55 Balanced news tone 46 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 248.08 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-5.0% over one week, +8.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -5.0% Price reacting lower
Trend fit Trend active 8.9% over four weeks
Fair value 36.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 30
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
simplywall.st 4
Pharmaceutical Executive 4
TradingView 3
The Globe and Mail 2
Stock Titan 2
GuruFocus 2
marketscreener.com 2

Event Lens

What the news is about

Classified themes
Market update 27
Deals and strategy 6
Analyst action 5
Earnings 3
Guidance 2
Capital return 1
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 46
TradingView Direct company coverage

Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?

AbbVie (ABBV) stock has seen an 8.9% year-to-date rise, driven by investor confidence in its post-Humira growth strategy, particularly the success of Skyrizi and Rinvoq. Despite patent expiry challenges for Humira, the company is bolstering its pipeline through acquisitions like

Tone
Positive 66/100
Event
Deals and strategy
Published
15 Jul 2026 15:07
Source
TradingView
24/7 Wall St. Direct company coverage

AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap

This article analyzes a "golden cross" technical signal for both AbbVie (ABBV) and Baxter International (BAX), evaluating which stock is better suited for an income-focused retirement portfolio. It concludes that AbbVie is a clear winner due to its robust dividend, strong financi

Tone
Positive 74/100
Event
Capital return
Published
15 Jul 2026 11:46
Source
24/7 Wall St.
StockInvest.us Direct company coverage

Red day on Tuesday for AbbVie stock after losing 1.31%

AbbVie stock (ABBV) fell by 1.31% on July 14, 2026, marking its seventh consecutive daily decline and resulting in a 3.76% drop over the last 10 days. Despite negative short-term signals like a sell signal from a pivot top point, the stock has a general buy signal from its long-t

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 00:53
Source
StockInvest.us
MarketWatch Direct company coverage

AbbVie Inc. stock outperforms competitors despite losses on the day

AbbVie Inc. (ABBV) shares fell by 1.30% to $244.78 on Tuesday, marking its seventh consecutive day of losses, despite a generally favorable trading session for the broader stock market. The S&P 500 Index rose by 0.38% and the Dow Jones Industrial Average increased by 0.02%. The a

Tone
Negative 39/100
Event
Market update
Published
14 Jul 2026 16:31
Source
MarketWatch
Yahoo! Finance Canada Direct company coverage

Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?

This article analyzes whether AbbVie (ABBV) is a wise investment, comparing its average brokerage recommendation (ABR) with the Zacks Rank. While Wall Street analysts have an optimistic outlook with an ABR of 1.61 (approximating Strong Buy), the Zacks Rank, a proprietary stock ra

Tone
Negative 35/100
Event
Guidance
Published
14 Jul 2026 13:37
Source
Yahoo! Finance Canada
Economies.com Direct company coverage

AbbVie price seeks a supportive bottom - Forecast today - 14-07-2026

AbbVie Inc. (ABBV) experienced a pullback due to bearish signals after reaching overbought territory, but is now seeking a higher low to rebuild positive momentum. Despite recent weakness, the stock remains above its 50-day Simple Moving Average, indicating a bullish outlook for

Tone
Positive 75/100
Event
Guidance
Published
14 Jul 2026 12:07
Source
Economies.com
The Globe and Mail Direct company coverage

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb

Donald Trump's administration has implemented voluntary drug-pricing agreements with major pharmaceutical companies like Pfizer, AbbVie, and Bristol Myers Squibb, aligning drug prices with those in comparable developed countries. While these deals introduce some pricing pressure,

Tone
Positive 61/100
Event
Market update
Published
14 Jul 2026 09:19
Source
The Globe and Mail
ABC11 News Direct company coverage

AbbVie pharmaceutical project moves forward in Durham: 'Huge deal'

Durham County leaders are considering a $15 million incentive package for AbbVie, a major pharmaceutical company planning a $1.4 billion investment in a new Durham campus. This project highlights the region's growing pharmaceutical industry and the role of local institutions like

Tone
Positive 71/100
Event
Deals and strategy
Published
13 Jul 2026 21:51
Source
ABC11 News
Stock Titan Direct company coverage

Apogee Therapeutics (NASDAQ: APGE) backs AbbVie’s $135.11‑per‑share all‑cash deal

Apogee Therapeutics (NASDAQ: APGE) has agreed to be acquired by AbbVie through a merger, where Apogee shareholders will receive $135.11 in cash per share. This all-cash deal represents a 53% premium to Apogee’s closing price on June 17, 2026, and a 63% premium to its 30-day volum

Tone
Positive 71/100
Event
Deals and strategy
Published
13 Jul 2026 21:15
Source
Stock Titan
GuruFocus Direct company coverage

ABBV Maintained by UBS -- Price Target Raised to $260

UBS analyst Michael Yee maintained a 'Neutral' rating for AbbVie (ABBV) while increasing the price target from $230.00 to $260.00. Despite the positive outlook reflected by the raised price target, GuruFocus indicates ABBV is currently overvalued by 16.4%, with a GF Value™ of $21

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 19:38
Source
GuruFocus
marketscreener.com Direct company coverage

BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating

BMO Capital has increased its price target for AbbVie (ABBV) from $258 to $300, while maintaining an "Outperform" rating on the stock. This adjustment reflects BMO Capital's continued positive outlook on the biopharmaceutical company. The report also notes other recent analyst ac

Tone
Positive 70/100
Event
Analyst action
Published
13 Jul 2026 14:52
Source
marketscreener.com
marketscreener.com Direct company coverage

UBS Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating

UBS has increased its price target for AbbVie (ABBV) shares to $260 from $230, while maintaining a Neutral rating on the stock. This adjustment comes amidst other analyst revisions for AbbVie, with firms like BMO Capital, BofA Securities, and RBC also updating their price targets

Tone
Positive 64/100
Event
Analyst action
Published
13 Jul 2026 14:07
Source
marketscreener.com
Market source Direct company coverage

AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty

AbbVie, though relatively young as a standalone company, has maintained its dividend growth inherited from Abbott, positioning itself as a Dividend King. The acquisition of Apogee Therapeutics for $10.9 billion is a strategic move to bolster its drug pipeline, particularly with d

Tone
Positive 67/100
Event
Deals and strategy
Published
12 Jul 2026 23:06
Source
Market source
ad-hoc-news.de Direct company coverage

AbbVie stock holds steady after a new U.S. market backdrop

AbbVie Inc. (US00287Y1091) remains a significant U.S. healthcare company, focusing on its diversified drug portfolio with strong exposure to immunology and aesthetics. The stock's stability is attributed to its broad therapeutic franchise, multiple revenue streams, and establishe

Tone
Positive 67/100
Event
Earnings
Published
12 Jul 2026 07:24
Source
ad-hoc-news.de